chufangao/CTO huggingface dataset:
Clinical trial NCT04158583: A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
Official title: An Open-Label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7296682, A CD25-Targeting, T-Regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumor
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Halted in order to focus on the ongoing combination of RO7296682 with Atezolizumab, evaluated in study BP42595, as a higher likelihood for efficacy is expected in combination with Atezolizumab as compared to the monotherapy setting.
Enrollment: 76.0 (ACTUAL)
Number of arms: 10.0
Start date: 2019-12-09
Primary completion date: 2022-07-21
Completion date: 2022-07-21
Baseline population: Safety population included all participants randomized to study treatment and who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not.
Plan to share individual participant data: NO
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03875911: Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy
Official title: A Prospective Randomized Clinical Trial Comparing Three Delivery Methods of Mitomycin-C for Trabeculectomy Surgery: Preoperative Subconjunctival Injection, Intraoperative Subconjunctival Injection, and Topical Application (Conventional Use) During Trabeculectomy Surgery
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Problems unique to COVID-19, incomplete data due to a high rate of dropout to minimize non-essential appointments and difficult subject recruitment
Enrollment: 19.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-30
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Baseline population: Not different from the assignment in Participation Flow. Participants can enroll two eyes in the study if both are eligible and trabeculectomy is recommended by the physician
Limitations and caveats: COVID-19 pandemic occurred during study meaning high rates of patients lost to follow-up, as non-emergent visits were canceled or postponed. This led to early termination which means we had a small number of subjects to analyze, especially those who completed all 12 months of follow-up. By the time pandemic restrictions eased, several other studies had published results on similar trials, making further enrollment unnecessary and further supporting early termination of the study.
Clinical trial NCT05462756: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
Official title: A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections
Acronym: QWINT-4
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 730.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-11
Primary completion date: 2024-02-27
Completion date: 2024-02-27
Plan to share individual participant data: YES
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT05045404: Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
Official title: A Phase II Study of Poziotinib and Ramucirumab in EGFR Exon 20 Mutant Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study closed due to funding, 0 patient accrual.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-16
Primary completion date: 2023-02-02
Completion date: 2023-02-02
Clinical trial NCT02801656: Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea
Official title: Fecal Microbiota Transplantation for Primary Therapy in Clostridium Difficile Diarrhea - A Placebo-blinded Randomized Clinical Trial
Sponsor: Memorial University of Newfoundland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Not funded
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-01
Primary completion date: 2022-09-01
Completion date: 2022-09-01
Plan to share individual participant data: YES
IPD sharing description: After analysis is completed, data will be released
Clinical trial NCT05860075: Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
Official title: A Phase 1 Clinical Study to Evaluate IMM01 Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Refractory or Recurrent Hematologic Malignancy
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: No expected efficacy was observed in subsequent extended phase.The company decided to initiatively terminate the development of IMM01 as monotherapy and fully promote clinical development of combination therapy.
Enrollment: 73.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-19
Primary completion date: 2022-10-26
Completion date: 2022-10-26
Clinical trial NCT04399538: Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
Official title: A PHASE 2A, 2-PART, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED, PARALLEL-GROUP (SPONSOR OPEN) STUDY TO ASSESS PHARMACODYNAMICS AND SAFETY OF PF-06865571 (DGAT2I) COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH PRESUMED NONALCOHOLIC STEATOHEPATITIS (NASH)
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 75.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-08-10
Primary completion date: 2022-03-31
Completion date: 2022-04-28
Baseline population: Baseline population included all participants who were randomized and received at least 1 dose of study intervention.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03881059: Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
Official title: A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 203.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-04-01
Primary completion date: 2020-04-27
Completion date: 2021-01-27
Baseline population: All treated participants
Clinical trial NCT04348292: Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
Official title: A Phase 1b Neoadjuvant Trial of Sirolimus Followed by Durvalumab (MEDI4736) in Resectable Non-small Cell Lung Cancer
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Accrual goal not met.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-22
Primary completion date: 2022-11-04
Completion date: 2022-11-04
Baseline population: diagnosed with Resectable Non-small Cell Lung Cancer
Limitations and caveats: This was a low accruing trial which amassed fewer patients than anticipated. Due to stalled enrollment, the study was terminated and did not reach completion.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04278872: Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
Official title: A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
Sponsor: Sojournix, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated early as the goal of determining a safe and efficacious dose for further development for the treatment of VMS was not met
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-09
Primary completion date: 2021-02-12
Completion date: 2021-04-07
Plan to share individual participant data: NO
Clinical trial NCT04560868: Development of a mHealth Intervention for Ambivalent Smokers
Official title: Development of a mHealth Intervention for Ambivalent Smokers
Sponsor: Kaiser Permanente (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-16
Primary completion date: 2021-09-27
Completion date: 2021-09-27
Limitations and caveats: The purpose of this pilot was to inform feasibility and acceptability of the experimental app among smokers who were ambivalent about quitting. Data were analyzed among participants who installed the app (n = 57). This pilot study was not powered to provide definitive answers about the efficacy of the intervention in promoting smoking abstinence. A larger trial is needed for this.
Plan to share individual participant data: NO
IPD sharing description: Data will not be shared.
Clinical trial NCT04662086: COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
Official title: COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 122.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-23
Primary completion date: 2022-05-03
Completion date: 2023-02-02
Limitations and caveats: This camostat arm did not meet its planned enrollment and did not achieve statistical power as specified in the protocol.
Plan to share individual participant data: NO
Clinical trial NCT03423147: Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor
Official title: A Randomized Trial to Determine if a Pre-operative Wash With a Chlorhexidine Gluconate Cloth and Chlorhexidine Gluconate Vaginal Scrub Reduces Infectious Morbidity in Patients Undergoing Cesarean Section After Labor
Acronym: PRACTICAL
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Poor enrollment, inability to achieve required number of subjects
Enrollment: 319.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-05
Primary completion date: 2021-02-11
Completion date: 2021-02-11
Clinical trial NCT02410239: MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)
Official title: MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD)
Sponsor: Masonic Cancer Center, University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Research cancelled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-06-30
Primary completion date: 2017-07-31
Completion date: 2022-07-31
Clinical trial NCT02771197: Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Official title: Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Sponsor: Northside Hospital, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-28
Primary completion date: 2022-08-03
Completion date: 2023-07-31
Plan to share individual participant data: NO
Clinical trial NCT03882970: A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Official title: A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Acronym: SURPASS-3
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1444.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-04-01
Primary completion date: 2020-12-11
Completion date: 2021-01-04
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT02759835: Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
Official title: A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-04-13
Primary completion date: 2022-05-25
Completion date: 2022-09-20
Plan to share individual participant data: YES
IPD sharing description: All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).
IPD time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing Plan (GDS) plan for as long as database is active.
IPD access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Clinical trial NCT03056014: Antioxidant Use in Diabetes to Reduce Oxidative Stress
Official title: Supplementation of N-acetylcysteine and Arachonic Acid in Type 1 Diabetes to Determine Changes in Oxidative Stress
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: COVID
Enrollment: 8.0 (ACTUAL)
Number of arms: 6.0
Start date: 2018-11-01
Primary completion date: 2020-03-12
Completion date: 2020-03-12
Plan to share individual participant data: NO
Clinical trial NCT03387514: Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
Official title: Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
Acronym: UW17104
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Termination of funding due to low subject enrollment due to change in standard of care systemic therapy which limited available patients treated with anti-angiogenesis or combined immune and anti-angiogenesis therapy for enrollment.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-08
Primary completion date: 2021-06-29
Completion date: 2021-06-29
Limitations and caveats: Due to change in standard of care system therapy to immune therapy during the course of this trial, patients did not proceed to anti-angiogenesis therapy or combined anti-angiogenesis therapy with immune therapy to allow for further PET or CT maging timepoints during the follow-up period of this trial. Therefore RECIST 1.1 response could not be assessed but PET SUVmax data is provided. Due to low enrollment for this issue, the study funding did not continue to allow for further study data.
Clinical trial NCT04980391: A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
Official title: A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study.
Enrollment: 384.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-08-03
Primary completion date: 2023-05-30
Completion date: 2023-05-30
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT04505592: Tenecteplase in Patients With COVID-19
Official title: Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-25
Primary completion date: 2022-03-10
Completion date: 2022-03-10
Plan to share individual participant data: NO
Clinical trial NCT03522207: Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient
Official title: Stabilisation de la qualité du Sommeil Chez le Sujet en Douleurs Orofaciales Chroniques - étude expérimentale en chassé croisé : Trazodone/ Placebo
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: shortstaff at sleep lab
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-15
Primary completion date: 2020-01-20
Completion date: 2020-01-20
Clinical trial NCT03209973: A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Official title: A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 70.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-21
Primary completion date: 2020-11-02
Completion date: 2020-11-02
Baseline population: Safety Analysis Set: All participants who received any dose of study drug.
Plan to share individual participant data: YES
Clinical trial NCT02184195: Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Official title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Acronym: POLO
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 154.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-12-16
Primary completion date: 2019-01-15
Completion date: 2023-01-27
Baseline population: Full analysis set consisted of all randomised patients analysed on an intent to treat basis.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT05130086: A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
Official title: A Phase 2 Open-Label Study to Evaluate the Safety and Pharmacokinetics of Oral Islatravir Once-Monthly in Trans and Gender Diverse Individuals on Gender-Affirming Hormone Therapy and at Low-Risk for HIV-1 Infection
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Business Reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-10-17
Primary completion date: 2024-03-25
Completion date: 2024-03-25
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf